Selskabets formål er at frembringe og kommereialisere teknologier til fremstilling af stoffer til brug indenfor lægemiddelindustrien ved screening af ikke-biologiske polymerer og lav-molekylære stoffer samt hermed naturlige forbundet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 118.4 mio. | -18.4 mio. | 173.8 mio. | 49.7 mio. | 77 | |
CVR: 26029708
Compared to 999 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Companies in the same industry and area
CVR 45436497
CVR 42731323
CVR 17826905
CVR 26392861
CVR 33687311
NUEVOLUTION A/S is currently facing financial challenges, as evidenced by its negative profit margins over the past three years, culminating in a loss of 18.4 million DKK in 2024 despite a revenue increase to 118.4 million DKK. The company has seen fluctuating revenues, peaking at 162.3 million DKK in 2021, but has since experienced a downward trend in profitability, with equity decreasing from 132.5 million DKK in 2021 to 49.7 million DKK in 2024. Key concerns include the significant losses and declining equity, which may impact its operational stability and growth potential within the competitive research and experimental development sector. Overall, NUEVOLUTION A/S is navigating a challenging financial landscape, necessitating strategic adjustments to improve its profitability and equity position.
AI-generated summary
Omari Clinton Wise joined the board
Adam Stewart Elinoff left the board
Jeffrey David Bernd joined the board
Adam Stewart Elinoff joined the board
Mikkel Kaasgaard Rasmussen left the board
Filippo Montano left the board
companydata.dk